CHARM Therapeutics is pioneering advancements in drug discovery through its innovative DragonFold technology, which focuses on protein-ligand co-folding. This proprietary platform utilizes 3D deep learning to accurately predict how proteins and ligands interact, enabling the identification of novel small molecule inhibitors aimed at treating cancers and other diseases with significant unmet medical needs. By addressing the challenges associated with targeting the 85% of the human proteome that remains undruggable, CHARM Therapeutics is positioned to transform the landscape of medicine and drug development.

The company combines its advanced computational methods with state-of-the-art laboratory facilities to validate AI-derived medicines, ensuring a rapid and effective transition from discovery to clinical application. With a strong emphasis on interdisciplinary collaboration, CHARM Therapeutics integrates expertise from various fields, including deep learning, structural biology, and cancer biology, to enhance the optimization of protein-ligand interactions. This holistic approach not only aims to create impactful therapies but also seeks to redefine the biopharmaceutical paradigm by leveraging cutting-edge technology in the quest for innovative treatments.

United Kingdom

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.

CHARM Therapeutics

Company Details